The proteomics firm reported increased annual losses and declining cash reserves, despite a slight uptick in TMT reagent sales. Management cites challenging market conditions but expresses optimism for future recovery.
The healthcare company will announce its 2024 results on April 10th and host an investor presentation on April 11th.
The diagnostics and research company has secured a substantial contract worth over US$1m from a US biopharmaceutical client, with work expected to be completed in the current and next financial years.
The healthcare services provider reports strong growth in orders for its proteomics services, with momentum continuing into 2025 and 2026. The company is securing additional financing to expand capacity to meet demand.
Proteome Sciences, a provider of contract proteomics services, reports a significant decline in revenue and profitability, raising concerns about its financial stability.
Proteomics services provider Proteome Sciences reports strong customer interest and growth outlook
Proteome Sciences secures major contract for clinical trial services
Proteomics specialist reports losses
Proteome Sciences opens new proteomics lab in San Diego biotech hub to serve growing US customer demand.
Proteome Sciences announces reduced revenues for 2023 due to project delays and challenging market environment.